Monofree (Dexamethasone Phosphate)

Dexamethasone phosphate, the active ingredient in Monofree, is a corticosteroid presented as an ophthalmic solution for ocular use. It is employed to treat inflammatory eye conditions such as postoperative inflammation, uveitis, and allergic conjunctivitis in adult patients. It is formulated for topical ocular administration, offering rapid anti‑inflammatory action with minimal systemic absorption.

GNH USA supplies Monofree as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Monofree, containing dexamethasone phosphate, acts on ocular inflammatory pathways to reduce swelling and discomfort. Postoperative inflammation: Reduces postoperative swelling, pain and redness after eye surgery. Uveitis: Controls intra‑ocular inflammation, decreasing cellular infiltrates and visual disturbance. Allergic conjunctivitis: Alleviates redness, itching and tearing associated with allergic eye reactions.

Monofree may cause ocular adverse reactions, ranging from mild irritation to serious complications. Common Side Effects: - Eye irritation or burning sensation - Transient increase in intra‑ocular pressure - Blurred vision - Excessive tearing Serious or Rare Side Effects: - Development of cataract with prolonged use - Secondary glaucoma - Severe allergic reaction such as conjunctival edema - Risk of corneal infection

When using Monofree, clinicians should observe several safety considerations to minimize risks. Monitor intra‑ocular pressure: Perform regular eye‑pressure checks during therapy. Avoid use in active ocular infections: Do not apply if viral, fungal or bacterial eye infection is present. Use cautiously in diabetic patients: May affect glucose control and require monitoring. Limit concurrent potent ocular steroids: Combine only under specialist supervision to prevent excess exposure. Store at room temperature: Keep in original packaging, protect from light and moisture.

Dexamethasone phosphate can interact with other ophthalmic or systemic agents, affecting efficacy or safety. Major Interactions (Avoid): - Concurrent systemic corticosteroids: May increase systemic glucocorticoid effects. - Potent CYP3A4 inhibitors: Can raise local drug concentration. - Combination with ocular NSAIDs: Heightens risk of corneal melting. Moderate Interactions (Monitor Closely): - Anticholinergic eye drops: May reduce therapeutic effect. - Antiviral agents for herpes keratitis: Require close observation. - Systemic immunosuppressants: Potential additive immunosuppression.